(MENAFN- ProactiveInvestors)Cancer diagnostics group VolitionRx Limited (NYSE:VNRX) has raised around US$12.8mln from its share placing which will be used to advance the business including for clinical studies and product commercialisation. Speaking to Proactive Investors Cameron Reynolds chief executive says he 'could not be happier' that the firm has raised enough money 'to get us to early 2018' without needing to offer warrants or issues shares at a big discount to the market price. 'It is an extremely challenging environment to be raising money' he adds noting that the 10% discount represents an 'excellent' price for the company. The firm issued around 3.7mln shares and a further 565384 additional stock as the over-allotment option was taken in full.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.